Compounded Tirzepatide: What It Is and Whether It Is Safe

In this guide, "compound tirzepatide" means a tirzepatide product made by a pharmacy rather than shipped by the drug's manufacturer.

These versions are prepared by a 503A compounding pharmacy or a 503B outsourcing facility, and they are not made under Eli Lilly's FDA approval for Zepbound.

The brand drug is precisely defined.

The FDA approved Zepbound (tirzepatide, Eli Lilly), used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity or adults with overweight plus at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

The same molecule is in Mounjaro, which is FDA-approved for type 2 diabetes, not as a weight-loss product.

A compounded product is not that drug.

FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed, and that they should be used only in patients whose medical needs cannot be met by an FDA-approved drug.

No. FDA's telehealth red flags for GLP-1s name "claims such as the compounded drug is the same as an FDA-approved drug" as a warning sign.

A compounded copy is not the approved product, and it is neither the brand nor a generic: FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing.

The differences are concrete.

Zepbound's FDA-reviewed label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes them in humans, including medullary thyroid carcinoma (MTC); the label also says the drug is contraindicated with a personal or family history of MTC or with MEN 2.

A compounded copy does not come with an FDA-reviewed label of that kind.

Dosing differs too.

FDA explains that compounded GLP-1 vials are often dosed in "units" on an insulin (U-100) syringe, and a "unit" is only a volume mark: how much drug it contains depends on that vial's concentration, which varies between compounders.

A compounded vial is therefore not automatically matched, dose for dose, to the branded product's labeled strengths.

The story runs through the shortage.

FDA had tirzepatide injection on the drug shortage list from 2022, declared the shortage resolved on October 2, 2024, re-evaluated that decision during litigation, and reaffirmed the resolution on December 19, 2024.

When the shortage ended, FDA's enforcement discretion for compounders ran on a clock.

For 503A pharmacies it ended when the federal district court denied a preliminary injunction on March 5, 2025, in Outsourcing Facilities Association v.

FDA; for 503B outsourcing facilities it ran until March 19, 2025.

As of FDA's April 1, 2026 update, tirzepatide appears on neither the drug shortage list nor the 503B bulks list, so 503B outsourcing facilities generally may not compound it from bulk drug substance.

What remains for a copy is narrow.

Under the 503A rules, a compounded GLP-1 with the same active ingredient, in a similar strength and given the same way as the approved drug, is treated as "essentially a copy" — unless the prescriber determines and documents that a change produces a significant difference for an identified individual patient.

Compounding was not banned outright, but the shortage-based justification for making copies is gone; what FDA's exception leaves for a copy is the documented, patient-specific determination.

Adding an ingredient does not automatically escape that rule.

FDA's published example involves an injectable combining semaglutide plus vitamin B12: at strengths within 10% of the approved products, the agency may still consider the combination essentially a copy.

The manufacturer has also gone after sellers, based on trade-press reporting: BioSpace reported in September 2023 that Eli Lilly sued medical spas, wellness centers and compounding pharmacies, including six med spas and wellness centers across Arizona, Florida, Georgia, Minnesota, South Carolina and Utah, alleging they passed off compounded tirzepatide as "Mounjaro." Those are allegations in reported lawsuits, not findings verified from court records, and the individual businesses are not named here.

The molecule-by-molecule picture, including the rules for compounded semaglutide, is on our compounded GLP-1 rules page.

Start with FDA's bottom line: compounded drugs are not reviewed for safety, effectiveness or quality before marketing, and FDA says they should be used only when an approved drug cannot meet a patient's needs.

Dosing is where FDA has documented concrete harm.

A July 2024 FDA alert described compounded semaglutide dosing errors, some requiring hospitalization: patients drew 5 to 20 times the intended dose from multi-dose vials, and clinicians miscalculated milligram-to-"units" conversions by 5 to 10 times, with confusion between milliliters, milligrams and "units" contributing.

That alert involved compounded semaglutide, not tirzepatide.

The mechanism FDA described, though, applies to compounded GLP-1 vials often dosed in "units": how much drug a "unit" holds depends on the compounder's concentration, so the strength on the vial is the number that matters.

FDA also tracks reports after the fact.

As of May 31, 2026, the agency had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and it notes the counts are likely underreported because 503A pharmacies are not required to report adverse events and causation cannot always be determined.

These are report counts, not rates — they cannot be turned into a risk percentage.

Some reports are tied to prescribing.

FDA has received adverse-event reports linked to compounded semaglutide or tirzepatide prescribed above label doses — larger doses, more frequent doses, or faster titration — and describes some as serious.

FDA's handling advice for anyone using a compounded GLP-1 is specific:

• Discard a multi-dose vial within 28 days of first use, even if medication remains and even if the compounder's instructions say longer.
• Use a new sterile needle and syringe for every dose.
• Do not use an injectable GLP-1 that arrives warm or with inadequate refrigeration.

There is a counterfeit layer as well.

FDA is aware of fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that do not exist, or licensed pharmacies that did not actually make the product.

It has also warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled "for research purposes" or "not for human consumption," and urges consumers not to buy these products.

A clinic's answers to a handful of questions separate a careful program from a red-flag one.

FDA's telehealth red flags for GLP-1s are the frame: claiming a compounded drug is the same as an FDA-approved drug, deep discounts that seem too good to be true, no screening and prescription by a licensed doctor, no doctor available for questions, label spelling errors or wrong pharmacy addresses, or a pharmacy name you suspect is fraudulent.

Who may prescribe and supervise a GLP-1 at a med spa — a physician, NP or PA, and whether the exam happens in person or by telehealth — is set by state law, not by the FDA label, so the answer is a fair question in every state.

Our page on who can prescribe GLP-1s covers MD, DO, NP and PA rules and what a good-faith exam includes.

A program that will not answer these in writing has answered them.

FDA's guidance is to fill GLP-1 prescriptions at state-licensed pharmacies.

The alternative to a compounded copy is the approved drug itself: the Zepbound approval described at the top of this page, plus Mounjaro — the same molecule but FDA-approved for type 2 diabetes, not weight loss.

Zepbound is prescription-only: FDA tells patients to obtain a prescription from their doctor and fill it at a state-licensed pharmacy.

The brand's own cash prices are the number to hold any compounded quote against.

On Lilly's Zepbound site, as read on October 16, 2026, self-pay prices for a 1-month (28-day) supply of the KwikPen — or four vials at the 2.5 mg starter — were $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg, with a $449 offer for 7.5 mg to 15 mg when each refill is bought within 45 days of the previous one.

The fine print matters: Lilly says the $299 starting price applies to the KwikPen or the vial, not the single-dose pen, and that with commercial insurance that does not cover Zepbound, the single-dose pen can cost as low as $499 per month with its savings card.

These are Lilly's own dated prices, and its terms can change.

For the branded drug's trials, side effects and dosing, read our tirzepatide guide.

However you search, the product questions come down to the checklist above: a licensed prescriber who screens you, a state-licensed pharmacy that actually made what is in the vial, documented clinical-difference paperwork when the product is a copy, and handling instructions that match FDA's advice.

The questions are for the clinic; the judgment is for a licensed prescriber who has examined you.

Whether a tirzepatide product fits your health history is a medical decision, and this page is the background, not the prescription.